Janssen and Fate Collaborate to Develop iPSC-derived CAR-T and NK Therapies

On Thursday, April 2, Fate Therapeutics announced a multi-year collaboration with Janssen to develop and commercialize new off-the-shelf CAR-NK and CAR-T cell products derived from induced pluripotent stem cells (iPSCs). As part of the agreement, Fate will apply its iPSC product platform and Janssen will contribute proprietary antigen-binding domains for up to four tumor-associated antigen targets. Below, FENIX provides highlights from the deal and analysis of how Janssen’s ability to develop off-the-shelf cell therapies, potentially also targeting solid tumors, could strengthen the company’s position in the cell therapy field.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.